Skip to main content

Roivant Sciences Ltd.

corporate_fare Company Profile

Roivant Sciences Ltd.

ROIV·NASDAQ·Life Sciences·CIK 0001635088

Roivant Sciences Ltd. is a biopharmaceutical company focused on developing and commercializing medicines. The company's pipeline includes several product candidates. Brepocitinib, a small molecule inhibitor of JAK1 and TYK2, is currently under review at the FDA for dermatomyositis with a PDUFA Date of 3Q 2026. It is also in Phase 3 development for non-infectious uveitis and cutaneous sarcoidosis, and in Phase 2b/3 development for lichen planopilaris, all under the subsidiary Priovant. IMVT-1402, a fully human monoclonal antibody targeting FcRn, is in development across several IgG-mediated autoimmune indications under the subsidiary Immunovant. These include Phase 2/3 trials for Difficult-to-Treat Rheumatoid Arthritis, Graves' Disease, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Sjögren's Disease, as well as a Phase 2 trial for Cutaneous Lupus Erythematosus. Mosliciguat, an inhaled sGC activator, is in Phase 2 development for pulmonary hypertension associated with interstitial lung disease under the subsidiary Pulmovant. Roivant advances its pipeline by creating subsidiaries, referred to as "Vants," to develop and commercialize its medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups that complement its biopharmaceutical business.

Roivant Sciences Ltd. (NASDAQ:ROIV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for ROIV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ROIV spans 10-Q, 8-K, 4, 144.

Recent high-impact activity:

  • Roivant 10-Q: $4.2B Cash, $191.6M Quarterly Loss, New Immunovant Derivative Suit
  • Roivant Q2: LISRAYA Hits $31M in First 5 Weeks; IMVT-1402 Wins D2T RA Endpoint
  • Roivant Posts $31M Q2 Revenue, Loss Narrower Than Street Expected
  • Roivant's Brepocitinib Meets Primary Endpoint in Both Phase 3 NIU Trials
  • Brepocitinib Hits Both Phase 3 Uveitis Trials, Cutting Treatment Failure Risk ~75%

Financial Snapshot

Fiscal year ended March 31, 2026
Revenue
$8.26M
Net Income
-$299.77M
Diluted EPS
-$0.54
Op. Cash Flow
-$750.35M
Free Cash Flow
-$758.56M
Operating Income
-$515.07M
Cash & Equivalents
$1.42B
Debt / Equity
0.00×
Net Margin
-36.29×
Shares Outstanding
720.35M sh
Source: 10-K · filed 2026-05-20 · accession 0001635088-26-000061

Short Interest & Short Volume

6.07 days to cover

FINRA reported short interest of 45,513,591 shares in ROIV as of the October 30, 2026 settlement, a 12.9% increase from the prior period — about 6.1 days to cover at its recent average daily volume. On November 20, 2026, 72.5% of ROIV volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)45,513,591 shares as of October 30, 2026
Change vs prior period▲ 12.9%
Days to cover6.07 at avg daily volume of 7,503,616
Daily short volume (FINRA facilities)72.5% of 1,204,841 shares on November 20, 2026
5-day average short volume53.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with R →
$38.68 +0.06% today
52-week range · as of 2026-11-09 $19.79 – $42.5
Market cap
$28.01B
Volume
4M (0.5× avg)
3-mo avg 7.6M
Live data · 2026-11-21 09:56 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ROIV - Latest Insights

ROIV
Nov 09, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.37
Real-time Price: $38.68 info
Change: -$2.69 (-7%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.00
Real-time Price: $38.68 info
Change: -$2.32 (-6%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $40.39
Real-time Price: $38.68 info
Change: -$1.71 (-4%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $38.68 info
Change: +$2.48 (+7%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $38.68 info
Change: +$2.08 (+6%) info
Market Cap: $28.008B info
ROIV
Sep 23, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $37.74
Real-time Price: $38.68 info
Change: +$0.940 (+2%) info
Market Cap: $28.008B info
ROIV
Sep 14, 2026, 7:22 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $40.95
Real-time Price: $38.68 info
Change: -$2.27 (-6%) info
Market Cap: $28.008B info
ROIV
Sep 08, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.29
Real-time Price: $38.68 info
Change: -$2.61 (-6%) info
Market Cap: $28.008B info
ROIV
Aug 28, 2026, 4:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.86
Real-time Price: $38.68 info
Change: +$3.82 (+11%) info
Market Cap: $28.008B info
ROIV
Aug 27, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $37.81
Real-time Price: $38.68 info
Change: +$0.8716 (+2%) info
Market Cap: $28.008B info
ROIV
Aug 27, 2026, 3:18 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $37.28
Real-time Price: $38.68 info
Change: +$1.40 (+4%) info
Market Cap: $28.008B info
ROIV
Aug 18, 2026, 9:00 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $37.30
Real-time Price: $38.68 info
Change: +$1.38 (+4%) info
Market Cap: $28.008B info
ROIV
Aug 06, 2026, 7:28 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $35.10
Real-time Price: $38.68 info
Change: +$3.58 (+10%) info
Market Cap: $28.008B info
ROIV
Aug 06, 2026, 7:13 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.10
Real-time Price: $38.68 info
Change: +$3.58 (+10%) info
Market Cap: $28.008B info
ROIV
Aug 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $35.10
Real-time Price: $38.68 info
Change: +$3.58 (+10%) info
Market Cap: $28.008B info
ROIV
Jun 30, 2026, 8:38 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $35.39
Real-time Price: $38.68 info
Change: +$3.29 (+9%) info
Market Cap: $28.008B info
ROIV
Jun 30, 2026, 7:59 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $35.39
Real-time Price: $38.68 info
Change: +$3.29 (+9%) info
Market Cap: $28.008B info
ROIV
Jun 29, 2026, 6:23 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $34.74
Real-time Price: $38.68 info
Change: +$3.94 (+11%) info
Market Cap: $28.008B info
ROIV
Jun 26, 2026, 4:10 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $34.07
Real-time Price: $38.68 info
Change: +$4.61 (+14%) info
Market Cap: $28.008B info
ROIV
May 20, 2026, 7:25 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $38.68 info
Change: +$8.68 (+29%) info
Market Cap: $28.008B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets